Literature DB >> 22412042

HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?

M Iorfida1, S Dellapasqua2, V Bagnardi3, A Cardillo2, N Rotmensz3, M G Mastropasqua4, L Bottiglieri4, A Goldhirsch5, G Viale4, M Colleoni2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22412042     DOI： 10.1093/annonc/mds064

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.

Authors:  Eleonora Brunello; Giuseppe Bogina; Emilio Bria; Marco Vergine; Giuseppe Zamboni; Serena Pedron; Isabella Daniele; Jenny Furlanetto; Luisa Carbognin; Marcella Marconi; Erminia Manfrin; Merdol Ibrahim; Keith Miller; Giampaolo Tortora; Annamaria Molino; Bharat Jasani; Serena Beccari; Franco Bonetti; Marco Chilosi; Guido Martignoni; Matteo Brunelli
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-28       Impact factor: 4.553

2.  HER2 status determination: analyzing the problems to find the solutions.

Authors:  Irene Terrenato; Ilaria Pennacchia; Simonetta Buglioni; Marcella Mottolese; Vincenzo Arena
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

3.  FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.

Authors:  Stella Petroni; Lucia Caldarola; Rachele Scamarcio; Francesco Giotta; Agnese Latorre; Anita Mangia; Giovanni Simone
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967

4.  Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.

Authors:  Gabriele Zoppoli; Anna Garuti; Gabriella Cirmena; Ludovica Verdun di Cantogno; Cristina Botta; Maurizio Gallo; Domenico Ferraioli; Enrico Carminati; Paola Baccini; Monica Curto; Piero Fregatti; Edoardo Isnaldi; Michela Lia; Roberto Murialdo; Daniele Friedman; Anna Sapino; Alberto Ballestrero
Journal:  J Transl Med       Date:  2017-05-01       Impact factor: 5.531

5.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

6.  Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.

Authors:  A Borley; T Mercer; M Morgan; P Dutton; P Barrett-Lee; M Brunelli; B Jasani
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.